The company may no longer be operating, as it may be out of business. Find out why through their latest events.
BerGenBio Past Earnings Performance
Past criteria checks 0/6
BerGenBio's earnings have been declining at an average annual rate of -7%, while the Biotechs industry saw earnings growing at 15.5% annually. Revenues have been declining at an average rate of 66.5% per year.
Key information
-7.05%
Earnings growth rate
12.87%
EPS growth rate
Biotechs Industry Growth
17.04%
Revenue growth rate
-66.50%
Return on equity
-149.36%
Net Margin
-53,785.59%
Next Earnings Update
30 Apr 2024
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How BerGenBio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OTCPK:BRRG.F Revenue, expenses and earnings (NOK Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 23
0
-190
49
0
30 Sep 23
0
-226
61
0
30 Jun 23
0
-258
60
0
31 Mar 23
0
-293
64
0
31 Dec 22
0
-302
64
0
30 Sep 22
1
-294
62
0
30 Jun 22
1
-304
74
0
31 Mar 22
1
-309
71
0
31 Dec 21
1
-309
71
0
30 Sep 21
1
-314
71
0
30 Jun 21
1
-311
61
0
31 Mar 21
1
-290
57
0
31 Dec 20
1
-257
52
0
30 Sep 20
0
-241
48
0
30 Jun 20
0
-218
40
0
31 Mar 20
0
-204
38
0
31 Dec 19
9
-199
35
0
30 Sep 19
11
-193
32
0
30 Jun 19
11
-186
36
0
31 Mar 19
11
-182
33
0
31 Dec 18
2
-192
32
0
30 Sep 18
0
-188
32
0
30 Jun 18
0
-186
29
0
31 Mar 18
0
-171
28
0
31 Dec 17
0
-182
28
0
30 Sep 17
0
-162
21
0
30 Jun 17
0
-142
16
0
31 Mar 17
0
-175
14
0
31 Dec 16
0
-130
12
0
30 Sep 16
0
-127
18
0
30 Jun 16
0
-128
22
0
31 Mar 16
0
-82
24
0
31 Dec 15
0
-72
23
0
30 Sep 15
0
-70
20
0
30 Jun 15
0
-64
17
0
31 Mar 15
1
-57
15
0
31 Dec 14
1
-58
15
0
Quality Earnings: BRRG.F is currently unprofitable.
Growing Profit Margin: BRRG.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BRRG.F is unprofitable, and losses have increased over the past 5 years at a rate of 7% per year.
Accelerating Growth: Unable to compare BRRG.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BRRG.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.1%).
Return on Equity
High ROE: BRRG.F has a negative Return on Equity (-149.36%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2024/02/26 01:26
End of Day Share Price
2023/11/29 00:00
Earnings
2023/12/31
Annual Earnings
2023/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BerGenBio ASA is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.